Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 21.50 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 4.59 | Oscillator | Buy |
| Williams %R (14) | -96.48 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.22 (Hist 0.03) | Oscillator | Buy |
| Average Directional Index (14) | 57.18 (+DI 9.0 / -DI 40.1) | Trend | Strong Sell |
Current price $0.761
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 23, 26 |
| EMA 20 | 1.00 | MA | Strong Sell |
| SMA 20 | 0.92 | MA | Strong Sell |
| EMA 50 | 1.42 | MA | Strong Sell |
| SMA 50 | 1.62 | MA | Strong Sell |
| SMA 200 | 3.31 | MA | Strong Sell |
| Craig-Hallum |
| maintain |
| Buy |
| Buy |
| Sep 23, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 23, 26 | Wedbush | downgrade | Outperform | Neutral |
| Sep 23, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 23, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Aug 7, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Apr 28, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Apr 28, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Apr 27, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | CMPX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.8x | -7.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.5x | EPS est. -0.50 | Discount |
| Price / Book | 0.9x | 2.3x | Discount |
| Price / Sales | — | 46.8x | Discount |
| EV / EBITDA | -1.5x | -7.1x | Discount |
| Return on equity | -38.7% | — | Weak |
| Gross margin | 0.0% | 20.0% | Below hist. |
| Debt / Equity | 0.06 | 0.03 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -0.05 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Lerner Neil | officer: Chief Accounting Officer | P-Purchase | 20,000 @ $0.92 | $18.40K |
| Sep 24, 26 |
| Lerner Neil |
| officer: Chief Accounting Officer |
| P-Purchase |
| 2,500 @ $1.14 |
| $2.85K |
| Apr 29, 26 | Lerner Neil | officer: Chief Accounting Officer | P-Purchase | 15,000 @ $1.89 | $28.35K |
| Apr 29, 26 | Anderman Jonathan | officer: General Counsel | P-Purchase | 25,000 @ $1.89 | $47.25K |
| Apr 29, 26 | Anderman Jonathan | officer: General Counsel | A-Award | 25,000 @ $1.89 | $47.25K |
| Apr 29, 26 | Lerner Neil | officer: Chief Accounting Officer | A-Award | 15,000 @ $1.89 | $28.35K |
| Feb 8, 26 | Schuetz Thomas J. | director, officer: CHIEF EXECUTIVE OFFICER | F-InKind | 36,687 @ $6.52 | $239.2K |
| Jan 9, 26 | Schuetz Thomas J. | director, officer: CHIEF EXECUTIVE OFFICER | F-InKind | 46,777 @ $5.35 | $250.3K |
Stock news · updated daily
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel in patients with previously treated, advanced biliary tract cancer (BTC) in the Journal of Clinical Oncology (JCO). The results are also being presented today by Nilofer S. Azad, M.D., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The full publication is available via open access at https://ascopubs.org/toc/jco/0/ja.
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application (BLA) submission for tovecimig in patients with previously treated, advanced biliary tract cancer (BTC).
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year. Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.11 | -0.13 | Miss -17.5% | — |
| May 5, 2026 | -0.10 | -0.10 | Beat 0.0% | — |
| Mar 5, 2026 | -0.10 | -0.09 | Beat 10.0% | — |
| Nov 5, 2025 | -0.14 | -0.08 | Beat 42.9% | — |
| Aug 11, 2025 | -0.13 | -0.14 | Miss -7.7% | — |
| May 8, 2025 | -0.12 | -0.12 | Beat 0.0% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 2, 2026 | 2026-10-02 08:00:24 | View |
| 4 | Sep 25, 2026 | 2026-09-25 08:01:13 | View |
| 8-K | Sep 22, 2026 | 2026-09-22 08:30:16 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 15:59:52 | View |
| SC 13G | Aug 7, 2026 | 2026-08-07 09:13:12 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 08:00:55 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 07:30:20 | View |
| 8-K | Jul 1, 2026 | 2026-07-01 17:00:22 | View |
| 8-K | Jun 23, 2026 | 2026-06-22 17:45:16 | View |
| 8-K | Jun 11, 2026 | 2026-06-11 16:00:49 | View |
Proxy statement (DEF 14A) disclosures